Navigation Links
MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study,of Aquavan Injection in Patients Undergoing Bronchoscopy

safety profile. The most frequently observed sedation-related adverse event in this study was transient hypotension (3%). No adverse events led to procedure or study drug discontinuation.

About Aquavan(R) (fospropofol disodium) Injection

Aquavan(R) (fospropofol disodium) Injection, a proprietary water-soluble prodrug of propofol that after intravenous injection is rapidly converted by an enzyme (alkaline phosphatase) in the body into propofol, is a product candidate in development for sedation of patients undergoing short surgical or diagnostic procedures. Aquavan has not been approved for marketing by the U.S. Food and Drug Administration (U.S. FDA) or any other regulatory agencies.

About MGI PHARMA

MGI PHARMA, INC. is a biopharmaceutical company focused in oncology and acute care that acquires, researches, develops and commercializes proprietary products that address the unmet needs of patients. MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. The Company directly markets its products in the U.S. and collaborates with partners to reach international markets. For more information about MGI PHARMA, please visit www.mgipharma.com.

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of MGI PHARMA's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause MGI PHARMA's results to differ materially from those expressed or implied by such forward-looking statements include, bu
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:9/19/2014)... 19, 2014 Harwood Feffer LLP ( www.hfesq.com ... directors of PDL BioPharma, Inc. ("PDL" or the "Company") ... has breached its fiduciary duties to shareholders or violated ... 2014, the Company disclosed: "On September 11, 2014, [PDL] ... Ernst & Young LLP ("EY"), that it was resigning ...
(Date:9/19/2014)... Pa. , Sept. 19, 2014  Today ... two new variable angle plating systems featuring its ... surgeons can adapt screw trajectory to match patient ... specific fragments of bone. The systems are being ... & Ankle Society (AOFAS) and the International Federation ...
(Date:9/19/2014)... , Sept. 19, 2014 The Parenteral Drug ... harmonize global post-approval changes protocols. The ... the topic expressed by industry participants and regulatory authority ... this month in Washington, DC . ... on hand for the workshop. Attendees indicated openness to ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2
... Diagnostics, an FDA licensed and ISO certified biomedical ... CulGenex™, a new brand of culture media, biological ... purification kits, and transfection reagents for molecular biology ... Crowe (molecular biologist from the University of Pittsburgh) ...
... Kan., Sept. 16 ScriptPro has been awarded a ... National Institutes of Health (NIH) in ... and drug information systems will be implemented in the ... control and identification of drugs and enhance the safety ...
Cached Medicine Technology:CulGenex™ by Hardy Diagnostics Assists Medical Researchers! 2National Institutes of Health Chooses ScriptPro for Pharmacy Automation 2
(Date:9/20/2014)... New York, New York (PRWEB) September 20, 2014 ... of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in ... notes that yet another insurer has announced plans ... a statement posted on its website last month, ... such procedures effective November 1, 2014. The insurer ...
(Date:9/20/2014)... 2014 The excitement is building up once again ... Carolina. This year the Surry Arts Council will be celebrating ... the country who are still fans of the Andy Griffith Show. ... that aired on CBS from 1960 through 1968. The show ... television history. Mount Airy, North Carolina is where the show ...
(Date:9/20/2014)... Recently, UWDress.com, an innovative company that provides ... outfits, has launched a special offer for its brand ... popular among worldwide clients. Now, all the company’s new ... on its website. , Additionally, the firm also ... world. Great custom made items can be ordered at ...
(Date:9/20/2014)... Wisconsin (PRWEB) September 20, 2014 QueenBeeTickets.com ... the young star’s tour performances. She will visit many ... of February until the 16th of April. , ... Grande Honeymoon Tour tickets at QueenBeeTickets.com. , The star’s ... opportunity to see their favorite young singer in a ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 The Arizona ... College (MCC) is celebrating National Manufacturing Day by opening ... enhanced machining, processing and additive manufacturing labs will be ... 3, 2014 at MCC’s Southern and Dobson campus (1833 ... in southeast Lot D. , The AzAMI at MCC ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Discounted 2014 Prom Dresses Provided By Innovative Company UWDress.com 2Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2
... Gist, D.D.S., who practices general dentistry in Flint, Mich., was ... during a meeting of the ADA House of Delegates ... ADA presidency in October 2010 and will lead the more ... Dr. Gist will be the ADA,s first African-American president. , ...
... , - Significant variation exists in the quality of ... disease in U.S. hospitals. , - Hospitals receiving performance ... Guidelines (GWTG) quality improvement program appear to have better ... DALLAS, Oct. 6 Hospitals receiving performance awards from ...
... Winner Medical Group Inc. (OTC Bulletin Board: WWIN; "Winner ... largest exporter by volume in the medical dressing industry ... to list its common stock on NYSE Amex. , ... on Thursday, October 8, 2009, until which time its ...
... prevention or delay of full-blown disease seen in treated ... Among patients who show early signs of multiple sclerosis, ... halve the risk that they will develop full-blown disease, ... who are diagnosed with multiple sclerosis first show signs ...
... a leading brand in the weight management industry, launched Metabolife ... about positive, incremental changes to their lives and the lives ... with the launch of www.joinlessismore.com . , ... changes that delivers lasting results and weight loss is just ...
... West Bloomfield Hospital is embarking on a research study for ... , The clinical trial will test whether gene transfer ... who have lost responsiveness to drug therapy. , ... Parkinson,s disease patient population that has had a long-standing need ...
Cached Medicine News:Health News:Michigan Dentist Chosen President-Elect of the American Dental Association 2Health News:American Heart Association Quality News: Commitment to Quality Results in Lower Mortality Rates for Heart Attack and Heart Failure Patients 2Health News:American Heart Association Quality News: Commitment to Quality Results in Lower Mortality Rates for Heart Attack and Heart Failure Patients 3Health News:Winner Medical to Begin Trading on NYSE Amex on October 8, 2009 2Health News:Winner Medical to Begin Trading on NYSE Amex on October 8, 2009 3Health News:Early Drug Treatment May Cut Multiple Sclerosis Risk 2Health News:Communities Nationwide Learn 'Less Is More' from Metabolife(R) Through 1,000 In-Home Parties and An Interactive Site www.joinlessismore.com 2Health News:Communities Nationwide Learn 'Less Is More' from Metabolife(R) Through 1,000 In-Home Parties and An Interactive Site www.joinlessismore.com 3Health News:Henry Ford West Bloomfield Hospital Launches Gene Therapy Study for Parkinson's Disease 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: